Literature DB >> 11824699

Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.

J Ott1.   

Abstract

Summarized are psychonautic bioassays (human self-experiments) of pharmepéna--crystalline 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; O-Me-bufotenine), at times combined with crystalline beta-carbolines (harmaline or harmine). These substances were administered via intranasal, sublingual and oral routes, by way of pharmacological modeling of diverse South American shamanic inebriants (principally the snuffs epéna/nyakwana, prepared from barks of diverse species of Virola.) Intranasal, sublingual and oral psychoactivity of 5-MeO-DMT, and the 1967 Holmstedt-Lindgren hypothesis of the paricá-effect--intranasal potentiation of tryptamines by concomitant administration of monoamine-oxidase-inhibiting (MAOI) beta-carbolines from stems of Banisteriopsis caapi admixed with the snuffs--have been confirmed by some 17 psychonautic bioassays. Salient phytochemical and psychonautic literature is reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11824699     DOI: 10.1080/02791072.2001.10399925

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  22 in total

1.  The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Authors:  Alan K Davis; Joseph P Barsuglia; Rafael Lancelotta; Robert M Grant; Elise Renn
Journal:  J Psychopharmacol       Date:  2018-04-30       Impact factor: 4.153

2.  Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.

Authors:  J C Winter; D J Amorosi; Kenner C Rice; Kejun Cheng; Ai-Ming Yu
Journal:  Pharmacol Biochem Behav       Date:  2011-05-23       Impact factor: 3.533

3.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

4.  Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Bioanalysis       Date:  2009-04       Impact factor: 2.681

5.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

6.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

7.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Authors:  Hong-Wu Shen; Chao Wu; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

8.  Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2011-04-04       Impact factor: 3.922

Review 9.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

10.  Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2013-02-07       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.